Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals
What is the purpose of this trial?
This is a randomized, multi-center, prospective, double blind, two-stage, adaptive study. The primary objective is to demonstrate the efficacy of RP-1127 compared to placebo in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema. This objective will be addressed by comparing the proportion of RP-1127 treated patients and placebo treated patients with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC).
- 18 - 80
- Remedy Pharmaceuticals
- Last Updated:
- Study HIC#: